Merck

“Moderna and Merck are pairing a personalized mRNA cancer vaccine with Keytruda for melanoma”

“After working 10 years on an individualized treatment against cancer using mRNA technology, the phase three was positive... it's the first time that there is an agent in melanoma that is better than Keytruda alone.”